NASDAQ:TVRD Tvardi Therapeutics (TVRD) Stock Price, News & Analysis $1.96 -0.07 (-3.65%) As of 09:30 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Tvardi Therapeutics Stock (NASDAQ:TVRD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tvardi Therapeutics alerts:Sign Up Key Stats Today's Range$1.98▼$1.9850-Day Range$1.50▼$5.0052-Week Range$1.50▼$43.65Volume13,927 shsAverage Volume1.01 million shsMarket Capitalization$18.35 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingModerate Buy Company Overview Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Read More Tvardi Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreTVRD MarketRank™: Tvardi Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 329th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingTvardi Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTvardi Therapeutics has a consensus price target of $18.00, representing about 820.2% upside from its current price of $1.96.Amount of Analyst CoverageTvardi Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tvardi Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tvardi Therapeutics are expected to decrease in the coming year, from ($2.32) to ($3.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tvardi Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tvardi Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTvardi Therapeutics has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.25% of the float of Tvardi Therapeutics has been sold short.Short Interest Ratio / Days to CoverTvardi Therapeutics has a short interest ratio ("days to cover") of 0.04, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tvardi Therapeutics has recently increased by 7.01%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTvardi Therapeutics does not currently pay a dividend.Dividend GrowthTvardi Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.16 News SentimentTvardi Therapeutics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tvardi Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for TVRD on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Tvardi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tvardi Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.40% of the stock of Tvardi Therapeutics is held by insiders.Percentage Held by Institutions44.66% of the stock of Tvardi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tvardi Therapeutics' insider trading history. Receive TVRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVRD Stock News HeadlinesBTIG Research Has Lowered Expectations for Tvardi Therapeutics (NASDAQ:TVRD) Stock PriceAugust 1, 2026 | americanbankingnews.comTvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical TrialJuly 30, 2026 | quiverquant.comQThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.August 5 at 1:00 AM | Banyan Hill Publishing (Ad)Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109July 30, 2026 | globenewswire.comTvardi Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TVRDJuly 23, 2026 | benzinga.comTvardi Therapeutics Inc TVRDJuly 14, 2026 | morningstar.comMAnalysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)July 10, 2026 | theglobeandmail.comTvardi Therapeutics Reports Phase 1 Data for TTI-109July 8, 2026 | theglobeandmail.comSee More Headlines TVRD Stock Analysis - Frequently Asked Questions How have TVRD shares performed this year? Tvardi Therapeutics' stock was trading at $4.30 at the start of the year. Since then, TVRD stock has decreased by 54.5% and is now trading at $1.9560. How were Tvardi Therapeutics' earnings last quarter? Tvardi Therapeutics, Inc. (NASDAQ:TVRD) posted its quarterly earnings results on Friday, May, 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by $0.08. When did Tvardi Therapeutics IPO? Tvardi Therapeutics (TVRD) raised $60 million in an initial public offering on Friday, January 31st 2014. The company issued 5,000,000 shares at $11.00-$13.00 per share. How do I buy shares of Tvardi Therapeutics? Shares of TVRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/08/2026Today8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 2 weeks, TVRD's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TVRD Previous SymbolNASDAQ:TVRD CIK1346830 WebN/A Phone(203) 406-3700Fax203-567-1510Employees80Year Founded2004Price Target and Rating Average Price Target for Tvardi Therapeutics$18.00 High Price Target$61.00 Low Price Target$5.00 Potential Upside/Downside+786.7%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-64.17% Return on Assets-43.90% Debt Debt-to-Equity RatioN/A Current Ratio2.25 Quick Ratio2.25 Sales & Book Value Annual Sales$7.14 million Price / Sales2.67 Cash FlowN/A Price / Cash FlowN/A Book Value$2.23 per share Price / Book0.91Miscellaneous Outstanding Shares9,380,000Free Float8,687,000Market Cap$19.04 million OptionableN/A Beta0.39 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:TVRD) was last updated on 8/5/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
